VaxInnate Corporation Awarded Contract by the U.S. Government To Develop Recombinant Seasonal and Pandemic Flu Vaccines

CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines. VaxInnate is a biotechnology firm pioneering breakthrough technology for use in developing novel vaccines.